In one study, the authors demonstrated the combination of azacitidine and romidepsin with IFN-α has a high therapeutic potential based on its targeting of the most aggressive cellular components of colorectal cancer (i.e., metastatic cells and cancer stem cells) and the modulation of key survival and death pathways (including tumor ICD) [230]. This evidence concerns the gene IFNA2 and cancer.